How I monitor residual disease in chronic myeloid leukemia.

  • Radich J
  • Hungerford N
  • Thomas E
 et al. 
  • 2


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Molecular monitoring in chronic myeloid leukemia (CML) is a powerful tool to document treatment responses and predict relapse. Nonetheless, the proliferation of clinical trials and "guidelines" using the molecular endpoints of CML has outpaced practice norms, commercial laboratory application, and reimbursement practices, leaving some anxiety (if not confusion and despair) about molecular monitoring in the day-to-day treatment of CML. This article will try to address these issues by describing how I monitor CML, which, in summary, is with interest and without panic.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Jerald P Radich

  • N. Hungerford

  • ED. Thomas

  • RA. Clift

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free